American Heart Association Scientific Sessions 2016
Anthony Wierzbicki, Guy’s & St Thomas’ Hospitals, London discusses the implications of key trials at AHA 2016
Anthony Wierzbicki, Guy’s & St Thomas’ Hospitals, London discusses the implications of key trials at AHA 2016 GLAGOV ORION
read more »
GLAGOV in context: A view from the PCSK9 Forum Editors
The results of GLAGOV, reported at AHA Scientific Sessions and now published in JAMA (1) are of keen interest to the clinical community, with the major outcomes study FOURIER with evolocumab expected early in 2017. PCSK9 Forum Editors Professor Henry Ginsberg and Professor John Chapman…
read more »
GLAGOV results: Greater plaque regression with evolocumab
Results of the GLAGOV study (Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound) showed that treatment with the PCSK9 inhibitor evolocumab on top of statin led to further lowering of low-density lipoprotein cholesterol (LDL-C) beyond current guideline recommendations, and…
read more »
ORION I: Durability of response with PCSK9 RNA interference agent
The first in class PCSK9 RNA interference agent, inclisiran (previously known as ALN-PCSsc) showed sustained lowering of low-density lipoprotein cholesterol (LDL-C) on top of the standard of care including statins, according to early results from the ORION-1 study. Until recently, the main focus of therapeutic…
read more »
